Skip to main content

Home/ Groups/ OARS funding Cancer
MiamiOH OARS

PAR-15-155: Administrative Supplements to Promote Cancer Prevention and Control Researc... - 0 views

  •  
    The National Cancer Institute (NCI), through its Center for Global Health (CGH), seeks to promote cancer prevention and control (CPC) research in low- and middle-income countries (LMICs) through collaborations and research partnerships between the NCI-designated cancer centers and partner institutions in LMICs. Through this funding opportunity announcement (FOA), the NCI will provide administrative supplement awards to currently-funded P30 NCI-designated cancer center grantees to support pilot research plans that focus on cancer prevention and control. These supplements are designed to stimulate and strengthen CPC twinning programs between researchers at the NCI-designated cancer centers and institutions in LMICs. It is anticipated that outcomes of this supplement will include collaborative research grants between investigators at the NCI-designated cancer centers and LMIC institutions.
MiamiOH OARS

Cancer Research Education Grants Program - Courses for Skills Development - 0 views

  •  
    The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.
MiamiOH OARS

DoD Lung Cancer Career Development Award - 0 views

  •  
    The Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Key elements of this award are as follows: * Principal Investigator (PI): PIs must be research- or physician-scientists at an early stage of their independent research careers. PIs must be within 5 years of their first faculty appointment (or equivalent), and exhibit a strong desire to pursue a career in lung cancer research. * Mentorship: The mentor must be an experienced lung cancer researcher as demonstrated by a strong record of funding and publications in lung cancer research. In addition, the mentor must demonstrate a commitment to developing the PI's career in lung cancer research. * Career Development: A Career Development Plan is required and should be prepared with appropriate guidance from the mentor. A clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of lung cancer research should be included. The plan should outline how the PI will gain experience and training in lung cancer research. Because career development is the focus of this award, the PI's institution must demonstrate a commitment to the PI through a minimum of 40% protected time for the proposed research, though more protected time is highly desirable. * Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating death
MiamiOH OARS

DoD Breast Cancer Innovator Award - 0 views

  •  
    The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Since the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative, visionary individuals rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should have a past record of challenging the status quo, shifting paradigms by changing a field of research or approach to patient care, exhibiting high levels of creativity, and demonstrating promise for continued innovation in future work. These rare individuals will be able to articulate a vision for ending breast cancer that challenges current dogma and demonstrates an ability to look beyond tradition and convention. The PI is also expected to be established in his/her field and have demonstrated success at forming and leading effective partnerships and collaborations. To further the development of innovative individuals and spark the generation of novel ideas, applications are required to incorporate the mentoring of promising junior investigators. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. This professional effort in breast cancer research can be through a combination of this award and other current support. Individuals from other disciplines who will apply novel concepts to breast cancer are encouraged to submit. The PI is expected to assemble a research team that will provide the n
MiamiOH OARS

AGA-R. Robert & Sally Funderburg Research Award in Gastric Cancer * AGA - 0 views

  •  
    This award provides $50,000 per year for two years (total $100,000) to an established investigator working on novel approaches in gastric cancer research, including the fields of gastric mucosal cell biology; regeneration and regulation of cell growth (not as they relate to peptic ulcer disease or repair); inflammation (including Helicobacter pylori) as precancerous lesions; genetics of gastric carcinoma; oncogenes in gastric epithelial malignancies; epidemiology of gastric cancer; etiology of gastric epithelial malignancies; or clinical research in the diagnosis or treatment of gastric carcinoma. The award recipient will be acknowledged at the Research Recognition Celebration at Digestive Disease Week® 2016.
MiamiOH OARS

BLM WY Seed Collection and Genetic Research CESU - 0 views

  •  
    Collect populations of native forbs, shrubs and grasses for BLM Seeds of Success program, and conduct germination studies of target species to understand native species requirements.
MiamiOH OARS

Early-life Factors and Cancer Development Later in Life (R01) - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life.Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.
MiamiOH OARS

Increasing the Implementation of Evidence-Based Cancer Survivorship Interventions to In... - 0 views

  •  
    A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra
MiamiOH OARS

Increasing the Implementation of Evidence-Based Cancer Survivorship Interventions to In... - 0 views

  •  
    A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra
MiamiOH OARS

Damon Runyon Cancer Research Foundation - Cancer Research Award Programs - 0 views

  •  
    The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

    The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

    Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.
MiamiOH OARS

PAR-15-108: Multilevel Interventions in Cancer Care Delivery: Building from the Problem... - 1 views

  •  
    This Funding Opportunity Announcement (FOA) encourages applications that strengthen the science of multilevel effects of cancer care interventions by addressing the problem of incomplete follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers.

    The goals of this FOA are two-fold. First, this FOA seeks to advance the science of multilevel interventions in three ways: a) by establishing a common conceptualization of levels and the associated level-specific factors that affect practice; b) by standardizing metrics of the levels and their main effects on other levels and the individuals needing follow-up care; and c) by developing and standardizing the analysis of the effect of interventions on the individuals, groups, and organizations responsible for intervention implementation. Second, this FOA encourages applications that test interventions to improve the follow-up of abnormal screening in one or more ways, including: a) measuring multilevel effects of single-level interventions; b) comparing single vs. multilevel interventions; and c) testing multilevel interventions.
MiamiOH OARS

Multilevel Interventions in Cancer Care Delivery: Building from the Problem of Follow-u... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) encourages applications that strengthen the science of multilevel effects of cancer care interventions by addressing the problem of incomplete follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. The goals of this FOA are two-fold. First, this FOA seeks to advance the science of multilevel interventions in three ways: a) by establishing a common conceptualization of levels and the associated level-specific factors that affect practice; b) by standardizing metrics of the levels and their main effects on other levels and the individuals needing follow-up care; and c) by developing and standardizing the analysis of the effect of interventions on the individuals, groups, and organizations responsible for intervention implementation. Second, this FOA encourages applications that test interventions to improve the follow-up of abnormal screening in one or more ways, including: a) measuring multilevel effects of single-level interventions; b) comparing single vs. multilevel interventions; and c) testing multilevel interventions.
MiamiOH OARS

PAR-15-104: Core Infrastructure and Methodological Research for Cancer Epidemiology Coh... - 0 views

  •  
    The Funding Opportunity Announcement (FOA) invites grant applications for targeted infrastructure support of the core functions of Cancer Epidemiology Cohorts (CECs) and methodological research. Through this FOA, the National Cancer Institute (NCI) will support infrastructure and core functions for existing or new CECs. This FOA will also lead to support of core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of the Division of Cancer Control and Population Sciences (DCCPS) at the NCI. 
MiamiOH OARS

PAR-15-103: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54) - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites cooperative agreement (U54) applications for the implementation of Comprehensive Partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI-designated Cancer Centers (CC). The purpose of this limited competition funding opportunity announcement (FOA) is to continue fostering and supporting intensive collaborations among investigators at ISUPS and CCs in order to develop stronger national cancer programs aimed at understanding the reasons behind the significant cancer disparities and related impacts on these populations. This FOA is intended for: (1) supporting active Comprehensive Partnerships under the U54 mechanism or inactive Comprehensive Partnerships but formerly supported by the U54 mechanism; and (2) elevating the promising U56 partnerships and other similar partnerships to the comprehensive status.
MiamiOH OARS

PAR-15-092: Exploratory/Developmental Grants Program for Basic Cancer Research in Cance... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.  
MiamiOH OARS

PAR-15-093: Basic Cancer Research in Cancer Health Disparities (R01) - 1 views

  •  
    This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention intervention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.
MiamiOH OARS

William T Grant > News - William T. Grant Scholars Program Application... - 0 views

  •  
    The William T. Grant Scholars Program is for early-career researchers in the social, behavioral, and health sciences. We encourage Scholars to tackle important questions that will advance theory, policy, and practice for youth. Applicants identify new methods, disciplines, or content they want to learn, and propose five-year research plans that foster their growth in those areas.
MiamiOH OARS

RFA-CA-15-003: Advanced Development and Validation of Emerging Molecular Analysis Techn... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies and validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been significantly evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, early detection and screening, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R33 applications where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed.

    This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.   
MiamiOH OARS

RFA-CA-15-002: Innovative Molecular Analysis Technologies for Cancer Research (R21) - 0 views

  •  
    This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research focused on the inception and early-stage development of highly innovative molecular or cellular analysis technologies for basic and clinical cancer research. The emphasis of this FOA is on supporting the development of novel molecular and cellular analysis capabilities with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular basis of cancer. If successful, these technologies should accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.

    This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
MiamiOH OARS

Ohio Cancer Grant - 0 views

  •  
    Grants awarded by Ohio Cancer Research Associates are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.
     
    All studies carried out as part of the proposed project must meet standards of informed consent for human subjects and/or proper care for animal subjects. Institutional approval of all research protocols involving human subjects or animal subjects must accompany the grant application.
« First ‹ Previous 421 - 440 of 607 Next › Last »
Showing 20 items per page